Klaus Gregorius

Klaus Gregorius

Company: MipSalus

Job title: Co-Founder & CSO

Seminars:

Panel Discussion: Tackling Ultra-Rare Inborn Errors of Metabolism: Addressing a Huge Unmet Medical Need 3:40 pm

This panel discussion will set to map out the future for ultra-rare inherited metabolic therapeutics. Analyze current and future treatment options and explore how a patient-centric approach to drug development can be utilized through collaborations with advocacy groups. This panel will also address the role of industry-academia collaborations to access and augment novel therapeutic innovations…Read more

day: Day One

Development of an Oral, Non-Systemically Acting Medicinal Product for the Treatment of Phenylketonuria (Pku) to Be Used as a Mono-Therapy 9:30 am

• The product is a nano formulation of phenylalanine-binding particles made of a synthetic polymer • Animal data confirms the potential for the product to be used as a mono-therapy for all types of PKU • The technology works as a platform for developing medicinal products for other similar rare, metabolic diseases such as Alkaptonuria…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.